
    
      The investigators primarily aim to observe the time to first relapse from initiation of
      tocilizumab or azathioprine treatment. The proportion of participants who experience
      relapse-free in one year follow-up will be compared.

      The secondary outcomes are to determine: The safety profile of tocilizumab and azathioprine
      in participants with NMO and whether tocilizumab improves visual function, Expanded
      Disability Status Scale (EDSS), et al.
    
  